New drug aims to curb nosebleeds in rare bleeding disorder

NCT ID NCT05406362

Ongoing Disease control Sponsor: Vaderis Therapeutics AG Source: ClinicalTrials.gov ↗

First seen Apr 04, 2026 · Last updated May 08, 2026 · Updated 4 times

Summary

This study tests a new drug called VAD044 in 75 adults with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent nosebleeds and anemia. The goal is to see if the drug is safe and can reduce the number, length, and severity of nosebleeds. Participants first receive either VAD044 or a placebo, then all may receive the drug in an open-label extension.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Hospices Civils de Lyon

Lyon, France
Hospital Universiati De Bellvitge

Barcelona, Spain
Hospital Universitario Ramón y Cajal

Madrid, Spain
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Ospedale Maggiore di Crema

Crema, Italy
St. Antonius Hospital

Nieuwegein, Netherlands
Universitair Ziekenhuis Gent

Ghent, Belgium

Conditions

Explore the condition pages connected to this study.

HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)